

In the Specification:

B<sup>2</sup> At page 1, line 7, please insert --This application claims the priority from United States Provisional Application No. 60/057,989, filed September 5, 1997.--

B<sup>3</sup> At page 3, lines 16-18, please delete "Figure 7 shows the effect of BMP-2 by adenoviral infection: infection efficiency rate [Figure 7A]; increasing proliferation [Figure 7B]; decreasing apoptosis [Figure 7C]; and enhancing osteoblastic differentiation [Figure 7D]." and please replace with --Figures 7A-7D show the results of infecting cells with adenovirus vectors and control results for PBS administration as a control. Figure 7A shows infection efficiency as measured by  $\beta$ -galactosidase staining; Figure 7B shows increased proliferation, as measured by BrdU incorporation; Figure C shows decreasing apoptosis; and Figure 7D shows enhancement of osteoblast differentiation as measured by alkaline phosphatase.--

B<sup>4</sup> At page 3, please delete lines 19-23, and replace with -- Figure 8 compares healing as measured by x-ray densitometry obtained after filling of experimental bone gaps with a BMP-2 impregnated collagen sponge (COLL), or BMP-2 expressing recombinant C3H, CHO or T5 cell lines.

Figure 9 compares relative fluorescence intensity in experimental bone gaps filled with a BMP-2 impregnated collagen sponge (COLL), or BMP-2 expressing recombinant C3H, CHO or T5 cell lines.

Figure 10 compares total calcified areas in experimental bone gaps filled with a BMP-2 impregnated collagen sponge (COLL), or BMP-2 expressing recombinant C3H, CHO or T5 cell lines. --

At page 9, line 7, please delete "differentiation" and replace with --different--.

At page 9, line 33, please rewrite "Dox ." as --Dox.-- (No space between the x and the

period).

At page 12, line 16, please delete "Paraffin" and replace with --paraffin--.

At page 17, line 24, please delete "osteoblasts" and replace with --osteoblast--.

At page 17, line 28, please insert a comma after "edges".

At page 23, line 35, please insert a space between "genetically" and "engineered".

At page 24, line 3, please delete "were" and replace with --was--.

At page 24, line 18, please delete "ware" and replace with --were--.

At page 26, line 34, please rewrite "3ug" as --3 µg--.

At page 35, line 32, please delete "USA)." and replace with --CA)--.

At page 36, line 19, please rewrite "slide ." as --slide.-- (No space between slide and the period).

At page 42, line 31, please delete "ÿ" and replace with --α--.

At page 43, line 21, please insert a space between "USA)" and "according".

At page 43, line 29, please insert a space between "the" and "murine".

At page 43, line 31, please insert --(SEQ ID NO:1)-- after  
"5'-CATCCCAGCCCTCTGAC-3'"

At page 43, line 32, please delete the period after "5'-CTTTCCCACCTGCTTGCA-3'".

At page 43, line 32, please insert --(SEQ ID NO:2).-- after  
"5'-CTTTCCCACCTGCTTGCA-3'"

At page 44, line 34, please delete "3H<sub>2</sub>O," and replace with --3H<sub>2</sub>O,--.

At page 47, line 32, please insert a space between "tissue" and "on".

At page 51, line 38, please insert a space between "against" and "puromycin".

At page 54, line 10, please delete "osteoathritis" and replace with --osteoarthritis--.

#### REMARKS

Claims 1-10 have been canceled without prejudice and new claims 11-23, which better claim the invention, have been presented. Support for progenitor cells is found at page 21, line 34, and support for pluripotent progenitor cell is found at page 8, line 35. The Specification has been amended to state the priority claim to U.S. Provisional Application No. 60/057,989, filed September 5, 1997 and to provide an improved description of Figures 7-10. The Specification has also been amended to correct inadvertent typographical errors. None of the amendments made herein constitute the addition of new matter.

#### The Sequence Listing

A sequence listing is provided herewith in compliance with Patent Office requirements. The content of the sequence listing is supported by the as-filed Specification at page 43, lines 29-32. The Listing is provided as paper and machine-readable form, together with a copy of the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.